Skip to content

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1 and Part 2) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2)
* Measurable multiple myeloma (MM)
* Eastern Cooperative Oncology Group performance status of 0-1

Exclusion Criteria:

* Condition that confounds the ability to interpret data from the study
* Known active or history of central nervous system (CNS) involvement of MM

Note: Other protocol-defined inclusion/exclusion criteria apply

Study Location

Tom Baker Cancer Center
Tom Baker Cancer Center
Calgary, Alberta
Canada

Contact Study Team

Primary Contact

Nizar Bahlis, Site 0013

4032202801
Local Institution - 0024
Local Institution - 0024
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Site 0024

Study Sponsored By
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Participants Required
More Information
Study ID: NCT06121843